The efficacy and safety of onartuzumab in patients with solid cancers: A meta-analysis of randomized trials

• Published in: Indian journal of cancer Vol. 58; no. 2; pp. 232 - 240
• Main Authors: Kim, Bum, Kim, Dalyong, Kim, Jung, Kim, Hyeong, Jang, Hyun
• Format: Journal Article
• Language: English
• Published: India Wolters Kluwer India Pvt. Ltd 01.04.2021; Medknow Publications and Media Pvt. Ltd; Medknow Publications & Media Pvt. Ltd
• Subjects: Analysis; Antibodies, Monoclonal - therapeutic use; Cancer; Cancer patients; Cancer therapies; Care and treatment; Clinical trials; Complications and side effects; Humans; Medical research; Medicine, Experimental; Meta-analysis; Monoclonal antibodies; Neoplasms - drug therapy; Neoplasms - pathology; Prognosis; Proto-Oncogene Proteins c-met - antagonists & inhibitors; Proto-Oncogene Proteins c-met - immunology; Randomized Controlled Trials as Topic - statistics & numerical data; Survival Rate; meta-analysis; reviewKey Message The addition of onartuzumab to the standard anticancer treatments had no survival benefit in patients with solid cancer; onartuzumab; Anti-MET inhibitor; review

Background: Onartuzumab, a humanized monovalent monoclonal antibody to the MET protein, has been tested in various cancers. We conducted a meta-analysis of randomized phase II and III clinical trials to investigate the efficacy and safety of onartuzumab in solid cancers. Methods: We searched PubMed,...